KR102919834B1 - Alk2 항체 및 그의 사용 방법 - Google Patents

Alk2 항체 및 그의 사용 방법

Info

Publication number
KR102919834B1
KR102919834B1 KR1020217015329A KR20217015329A KR102919834B1 KR 102919834 B1 KR102919834 B1 KR 102919834B1 KR 1020217015329 A KR1020217015329 A KR 1020217015329A KR 20217015329 A KR20217015329 A KR 20217015329A KR 102919834 B1 KR102919834 B1 KR 102919834B1
Authority
KR
South Korea
Prior art keywords
seq
alk2
delete delete
binding fragment
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020217015329A
Other languages
English (en)
Korean (ko)
Other versions
KR20210088591A (ko
Inventor
자스비르 에스. 시라
제니퍼 러셰이
Original Assignee
케로스 테라퓨틱스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 케로스 테라퓨틱스, 인크. filed Critical 케로스 테라퓨틱스, 인크.
Publication of KR20210088591A publication Critical patent/KR20210088591A/ko
Application granted granted Critical
Publication of KR102919834B1 publication Critical patent/KR102919834B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020217015329A 2018-10-23 2019-10-23 Alk2 항체 및 그의 사용 방법 Active KR102919834B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862749463P 2018-10-23 2018-10-23
US62/749,463 2018-10-23
PCT/US2019/057679 WO2020086730A1 (en) 2018-10-23 2019-10-23 Alk2 antibodies and methods of use thereof

Publications (2)

Publication Number Publication Date
KR20210088591A KR20210088591A (ko) 2021-07-14
KR102919834B1 true KR102919834B1 (ko) 2026-01-30

Family

ID=70331231

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217015329A Active KR102919834B1 (ko) 2018-10-23 2019-10-23 Alk2 항체 및 그의 사용 방법

Country Status (10)

Country Link
US (2) US12331124B2 (https=)
EP (1) EP3870613A4 (https=)
JP (2) JP7512272B2 (https=)
KR (1) KR102919834B1 (https=)
CN (2) CN118955715A (https=)
AU (1) AU2019364415A1 (https=)
BR (1) BR112021007660A2 (https=)
CA (1) CA3116900A1 (https=)
IL (1) IL282424A (https=)
WO (1) WO2020086730A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7504880B2 (ja) 2018-10-26 2024-06-24 ケロス セラピューティクス インコーポレイテッド Ａｌｋ２阻害剤の結晶形
CN114761013A (zh) 2019-09-27 2022-07-15 迪斯克医药公司 治疗骨髓纤维化和相关病症的方法
CN115362175A (zh) * 2020-02-11 2022-11-18 瑞泽恩制药公司 抗acvr1抗体及其用途
US12508262B2 (en) 2020-04-30 2025-12-30 Keros Therapeutics, Inc. Methods of using ALK2 inhibitors
WO2021231798A1 (en) 2020-05-13 2021-11-18 Disc Medicine, Inc. Anti-hemojuvelin (hjv) antibodies for treating myelofibrosis
WO2022098812A1 (en) 2020-11-04 2022-05-12 Keros Therapeutics, Inc. Methods of treating iron overload
WO2022240948A1 (en) * 2021-05-11 2022-11-17 Keros Therapeutics, Inc. Methods of using alk2 and alk3 antibodies
WO2023081212A1 (en) * 2021-11-02 2023-05-11 Keros Therapeutics, Inc. Methods of using alk2 inhibitors
US20240150474A1 (en) * 2022-10-27 2024-05-09 Regeneron Pharmaceuticals, Inc. Anti-acvri antibodies and their use in the treatment of trauma-induced heterotopic ossification

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100062001A1 (en) 2004-06-09 2010-03-11 Technion Research & Development Antibodies for selective apoptosis of cells
US20160075772A1 (en) 2014-09-12 2016-03-17 Regeneron Pharmaceuticals, Inc. Treatment of Fibrodysplasia Ossificans Progressiva
WO2016121908A1 (ja) * 2015-01-30 2016-08-04 学校法人埼玉医科大学 抗ａｌｋ２抗体
US20180180614A1 (en) 2015-03-26 2018-06-28 Vanderbilt University Antibody-mediated neutralization of ebola viruses

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009002418A (es) 2006-09-05 2009-04-23 Medarex Inc Anticuerpos para las proteinas morfogenicas oseas y receptores de estas y metodos para su uso.
CN102548617B (zh) 2009-03-30 2017-11-07 阿塞勒隆制药公司 Bmp‑alk3拮抗剂和促进骨生长的用途
US20130089560A1 (en) 2010-03-17 2013-04-11 Oncomed Pharmaceuticals Inc Bone morphogenetic protein receptor binding agents and methods of their use
WO2012065059A2 (en) 2010-11-12 2012-05-18 The General Hospital Corporation Treatment of atherosclerosis with bmp-alk3 antagonists
WO2015152183A1 (ja) 2014-03-31 2015-10-08 大日本住友製薬株式会社 進行性骨化性線維異形成症の予防剤及び治療剤
US12428484B2 (en) 2018-12-06 2025-09-30 Alexion Pharmaceuticals, Inc. Anti-ALK2 antibodies and uses thereof
CN115362175A (zh) 2020-02-11 2022-11-18 瑞泽恩制药公司 抗acvr1抗体及其用途
JP2023530316A (ja) 2020-06-16 2023-07-14 インサイト・コーポレイション 貧血の治療のためのａｌｋ２阻害剤
WO2022098812A1 (en) 2020-11-04 2022-05-12 Keros Therapeutics, Inc. Methods of treating iron overload
WO2022098821A1 (en) 2020-11-04 2022-05-12 Keros Therapeutics, Inc. Methods of treating lymphopenia
WO2022099166A1 (en) 2020-11-09 2022-05-12 Keros Therapeutics, Inc. Methods of treating cardiovascular-related disease
WO2022240948A1 (en) 2021-05-11 2022-11-17 Keros Therapeutics, Inc. Methods of using alk2 and alk3 antibodies

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100062001A1 (en) 2004-06-09 2010-03-11 Technion Research & Development Antibodies for selective apoptosis of cells
US20160075772A1 (en) 2014-09-12 2016-03-17 Regeneron Pharmaceuticals, Inc. Treatment of Fibrodysplasia Ossificans Progressiva
WO2016121908A1 (ja) * 2015-01-30 2016-08-04 学校法人埼玉医科大学 抗ａｌｋ２抗体
US20180118835A1 (en) 2015-01-30 2018-05-03 Saitama Medical University Anti-alk2 antibody
US20180180614A1 (en) 2015-03-26 2018-06-28 Vanderbilt University Antibody-mediated neutralization of ebola viruses

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Pang Jing et al, "ACVR1-Fc suppresses BMP signaling and chondroosseous differentiation in an in vitro model of Fibrodysplasia ossificans progressiva", BONE, PERGAMON PRESS, 2016, Vol.92, pp.29-36

Also Published As

Publication number Publication date
EP3870613A4 (en) 2022-08-03
JP7512272B2 (ja) 2024-07-08
US20250270333A1 (en) 2025-08-28
JP2024114820A (ja) 2024-08-23
CN113366019A (zh) 2021-09-07
CN118955715A (zh) 2024-11-15
CA3116900A1 (en) 2020-04-30
KR20210088591A (ko) 2021-07-14
CN113366019B (zh) 2024-08-27
AU2019364415A1 (en) 2021-05-20
EP3870613A1 (en) 2021-09-01
US12331124B2 (en) 2025-06-17
US20210253720A1 (en) 2021-08-19
BR112021007660A2 (pt) 2021-08-03
IL282424A (en) 2021-06-30
WO2020086730A1 (en) 2020-04-30
JP2022505585A (ja) 2022-01-14

Similar Documents

Publication Publication Date Title
KR102919834B1 (ko) Alk2 항체 및 그의 사용 방법
US12522646B2 (en) Activin receptor type II chimeras and methods of use thereof
US20230398118A1 (en) Methods of treating cardiovascular-related disease
US12440539B2 (en) Methods of using activin receptor type IIB variants
US20230372390A1 (en) Methods of treating lymphopenia
US20250270287A1 (en) Activin receptor type ii chimeras and methods of use thereof
US20240228583A1 (en) Activin receptor type ii chimeras and methods of use thereof
US12458693B2 (en) Methods of treating iron overload with a BMP inhibitor
EP4121090A1 (en) Methods of using activin receptor type iia variants
US20250188148A1 (en) Methods of administering an activin receptor type iib variant
US20250282877A1 (en) Methods of using alk2 and alk3 antibodies
HK40119616A (zh) Alk2抗体及其使用方法
HK40089125A (zh) 激活素受体ii型嵌合体以及其使用方法

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D22-EXM-PE0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

F11 Ip right granted following substantive examination

Free format text: ST27 STATUS EVENT CODE: A-2-4-F10-F11-EXM-PR0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

U12 Designation fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

Q13 Ip right document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE)